TENAYA THERAPEUTICS
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.
TENAYA THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2016-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.tenayatherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
248 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Global Site Tag
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Comet Therapeutics
Comet Therapeutics is a developer of therapies designed to treat orphan neurological disorders.
EIP Pharma
EIP Pharma Provides Healthcare Services.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Felix Biotechnology
Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Nine Square Therapeutics
Nine Square Therapeutics is a developer of novel therapies for movement disorders.
Pipeline Therapeutics
Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
PolyProx
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Relay Therapeutics
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Skyhawk Therapeutics
Skyhawk Therapeutics is a provvider of small molecule therapeutics designed to offer therapies that correct RNA expression.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Vaxcyte
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
T. Rowe Price
T. Rowe Price investment in Series C - Tenaya Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series C - Tenaya Therapeutics
RTW Investments LLC
RTW Investments LLC investment in Series C - Tenaya Therapeutics
Casdin Capital
Casdin Capital investment in Series C - Tenaya Therapeutics
GV
GV investment in Series C - Tenaya Therapeutics
The Column Group
The Column Group investment in Series C - Tenaya Therapeutics
RA Capital Management
RA Capital Management investment in Series C - Tenaya Therapeutics
Casdin Capital
Casdin Capital investment in Series B - Tenaya Therapeutics
Greenspring Associates
Greenspring Associates investment in Series B - Tenaya Therapeutics
The Column Group
The Column Group investment in Series B - Tenaya Therapeutics
Official Site Inspections
http://www.tenayatherapeutics.com Semrush global rank: 10.19 M Semrush visits lastest month: 29
- Host name: 113.175.239.35.bc.googleusercontent.com
- IP address: 35.239.175.113
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Tenaya Therapeutics"
Our Science - Tenaya Therapeutics
We have internalized the ability to create and integrate proprietary in vitro and in vivo models within our research organization. For our in vitro hiPSC-CM disease models, we use multiple …See details»
Leadership - Tenaya Therapeutics
He is also on the Board of Directors and executive committee of The Alliance for Regenerative Medicine (ARM), a non-profit advocacy organization supporting the cell and gene therapy …See details»
Tenaya Therapeutics - Crunchbase Company Profile
Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies …See details»
Tenaya Therapeutics - LinkedIn
Tenaya Therapeutics | 16,584 followers on LinkedIn. Scaling new heights in the fight against heart disease | Tenaya Therapeutics is a clinical stage biotechnology company. The Company was founded ...See details»
Corporate Governance - Tenaya Therapeutics, Inc.
The Investor Relations website contains information about Tenaya Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Tenaya Therapeutics to Participate at the 21st Annual Morgan …
Aug 31, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission …See details»
Investor Relations | Tenaya Therapeutics, Inc.
Nov 25, 2024 The Investor Relations website contains information about Tenaya Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.See details»
Tenaya Therapeutics Launches Operations of New Genetic …
Jun 16, 2022 Facility to Provide Clinical Supply of Lead Gene Therapy Programs TN-201 and TN-401 for Planned First-in-Human Studies. 94,000 sq. ft. Modular Facility has Initial …See details»
Our Programs - Tenaya Therapeutics
TN-201: MYBPC3 Gene Therapy Program for Genetic HCM. We are developing TN-201, an adeno-associated virus (AAV)-based gene therapy designed to treat adults and children with …See details»
Tenaya Therapeutics, Inc. (TNYA) - Stock Analysis
Nov 15, 2024 Website https://www.tenayatherapeutics.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 5 analysts, the average …See details»
Tenaya Highlights Growing Capabilities in AAV Manufacturing, …
May 3, 2023 Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com. Forward-looking …See details»
Tenaya Therapeutics Secures $106 Million in Series C Funding to ...
Mar 1, 2021 For more information, please visit www.TenayaTherapeutics.com and follow us on LinkedIn. Contacts. Wendy Ryan Ten Bridge Communications …See details»
Tenaya Therapeutics, Inc. (TNYA) - Yahoo Finance
Find the latest Tenaya Therapeutics, Inc. (TNYA) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Patients - Tenaya Therapeutics
A chronic, progressive condition, hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, and variations in the Myosin Binding Protein C3 (MYBPC3) gene …See details»
Tenaya Therapeutics Provides 2022 Business Updates | Tenaya ...
Jan 10, 2022 For more information, visit www.tenayatherapeutics.com. Forward-Looking Statements. This press release contains forward-looking statements as that term is defined in …See details»
Tenaya Therapeutics Doses First Patient in the MyPeak-1â„¢
May 10, 2023 SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission …See details»
Tenaya Therapeutics, Inc. (TNYA) Stock Price, News, Quote
Find the latest Tenaya Therapeutics, Inc. (TNYA) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Tenaya Therapeutics Announces Publication of TN-401 Gene …
Mar 18, 2024 Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com. Forward Looking …See details»
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results …
Nov 6, 2024 For more information, visit www.tenayatherapeutics.com. Forward Looking Statements This press release contains forward-looking statements as that term is defined in …See details»